triazoles has been researched along with HIV in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (40.54) | 29.6817 |
| 2010's | 21 (56.76) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, CR; Fulco, PP; Porter, AM | 1 |
| Chapman, D; Demarest, J; Dong, WW; Ellery, S; Harrigan, PR; Heera, J; Mo, T; Poon, AF; Swenson, LC; Valdez, H | 1 |
| Kravchenko, AV | 1 |
| Guo, J; Wu, Y; Xu, GG | 1 |
| Cavarelli, M; Chiappetta, S; Cossarizza, A; De Battista, D; De Biasi, S; Galli, L; Lazzarin, A; Malnati, M; Nozza, S; Pensieroso, S; Pogliaghi, M; Ripa, M; Scarlatti, G; Tambussi, G | 1 |
| Arroyo-Manzano, D; Blanco, JR; Bravo, I; Crespo, M; Garcia Del Toro, M; Herrero, C; Llibre, JM; Moreno, S; Pasquau, J; Rivero, A; Rojas-Liévano, JF | 1 |
| Abad, MA; de Pablo-Bernal, RS; Genebat, M; Jiménez-Mejías, ME; Leal, M; Martínez, O; Pacheco, YM; Pulido, I; Raffi-El-Idrissi Benhia, M; Ruiz-Mateos, E | 1 |
| Andrei, G; Boons, E; Daelemans, D; Jacquemyn, M; Landesman, Y; Neggers, JE; Nogueira, TC; Pannecouque, C; Shacham, S; Snoeck, R; Tamir, S; van den Oord, J; Vanstreels, E; Vercruysse, T | 1 |
| Carcenac, R; Cazabat, M; Cuzin, L; Delobel, P; Izopet, J; Jeanne, N; Nicot, F; Raymond, S; Requena, M | 1 |
| Basson, AE; Pelly, SC; Pribut, N; van Otterlo, WA; Veale, CG | 1 |
| De Luna-Romero, M; Dominguez-Molina, B; Genebat, M; Gonzalez-Serna, A; Leal, M; Muñoz-Fernández, MA; Pacheco, YM; Ruiz-Mateos, E; Tarancon-Diez, L | 1 |
| Dehaen, W; Hayat, MQ; Iram, S; Jana, S; Pannecouque, C; Thomas, J | 1 |
| Bowers, SJ; Mitchell, RJ; Potchoiba, MJ; Schroeder, CM; Small, HF; Walker, DK | 1 |
| Alcamí, J | 2 |
| Arenzana-Seisdedos, F | 1 |
| Delsol, E; Gutiérrez, C; Hernández, B; Moreno, S | 1 |
| Delgado, R | 1 |
| Camacho, A; Genebat, M; Leal, M; Rivero, A | 1 |
| Clotet, B; Clumeck, N; Fätkenheuer, G; Goodrich, J; Mayer, H; Saag, M; Sullivan, J; van der Ryst, E; Westby, M | 1 |
| Balzarini, J; McGuigan, C; Mehellou, Y | 1 |
| Ferrando-Martínez, S; Genebat, M; González-Serna, A; Leal, M; León, JA; Muñoz-Fernández, MA; Pulido, I; Rivas, I; Ruiz-Mateos, E; Sánchez, B | 1 |
| McKinnell, JA; Saag, MS | 1 |
| Larue, V; Lecourt, T; Micouin, L; Moumné, R; Seijo, B; Tisné, C | 1 |
| Poizot-Martin, I | 1 |
| Abbate, I; Bartolini, B; Bruselles, A; Capobianchi, MR; Chillemi, G; Ippolito, G; Narciso, P; Nicastri, E; Rozera, G; Tommasi, C | 1 |
| Abad, MA; Ferrando-Martinez, S; Garcia-Perganeda, A; Genebat, M; Gonzalez-Serna, A; Leal, M; Ruiz-Mateos, E | 1 |
| Chan, PL; Jacqmin, P; Lavielle, M; McFadyen, L; Weatherley, B | 1 |
| Anderson, DD; Ghosh, AK | 1 |
| Cui, Y; Jin, C; Li, X; Wu, N | 1 |
| Boesecke, C; Pett, SL | 1 |
| Mugavero, MJ; Napolitano, LA; Nevin, CR; Raper, JL; Saag, MS; Tamhane, A; Wilkins, SA; Willig, JH | 1 |
| Guo, J; Li, Z; Wu, Y; Zhou, Q | 1 |
| D'Cruz, OJ; Uckun, FM | 1 |
| Brunel, AS; Fraisse, T; Lechiche, C; Mauboussin, JM; Pinzani, V; Sotto, A | 1 |
| Mao, C; Sudbeck, EA; Uckun, FM; Venkatachalam, TK | 1 |
| Stephenson, J | 1 |
13 review(s) available for triazoles and HIV
| Article | Year |
|---|---|
[Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Treatment Outcome; Triazoles | 2013 |
Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications.
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Drug Discovery; HIV; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Structure-Activity Relationship; Triazoles; Virus Replication | 2014 |
[Viral entry as therapeutic target. Current situation of entry inhibitors].
Topics: Adult; Amides; Benzoates; CCR5 Receptor Antagonists; CD4 Antigens; Chemokines, CC; Chemokines, CXC; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Models, Molecular; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Spiro Compounds; Structure-Activity Relationship; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[Maraviroc efficacy in clinical studies on the development of the molecule].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Design; Drug Resistance, Multiple, Viral; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Multicenter Studies as Topic; Salvage Therapy; Treatment Outcome; Triazoles | 2008 |
[Mechanisms of resistance and failure of treatment with maraviroc].
Topics: Amino Acid Sequence; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; Genes, env; HIV; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Molecular Sequence Data; Multicenter Studies as Topic; Peptide Fragments; Receptors, CXCR4; Selection, Genetic; Treatment Failure; Triazoles; Virus Attachment; Virus Internalization | 2008 |
[At what time and with which combinations should maraviroc be indicated in the new antiretroviral treatment scenario?].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV; HIV Infections; Humans; Maraviroc; Membrane Fusion; Receptors, CXCR4; Salvage Therapy; Triazoles; Viral Load; Virus Attachment | 2008 |
[Conclusions and perspectives. Maraviroc].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, env; HIV; HIV Envelope Protein gp120; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Peptide Fragments; Receptors, CXCR4; Salvage Therapy; Selection, Genetic; Triazoles; Virus Attachment; Virus Internalization | 2008 |
Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
Topics: CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Peptide Fragments; Piperazines; Pyrimidines; Salvage Therapy; Triazoles; Virus Internalization | 2009 |
[CCR5-antagonists: contribution of a new antiretroviral class to the management of HIV infection].
Topics: Anti-Retroviral Agents; CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Triazoles; Viral Tropism | 2010 |
Tetrahydrofuran, tetrahydropyran, triazoles and related heterocyclic derivatives as HIV protease inhibitors.
Topics: Furans; Heterocyclic Compounds; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Pyrans; Structure-Activity Relationship; Triazoles | 2011 |
Clinical studies with chemokine receptor-5 (CCR5)-inhibitors.
Topics: Antibodies, Monoclonal; Antiviral Agents; CCR5 Receptor Antagonists; Coinfection; Cyclohexanes; Hepatitis C, Chronic; HIV; HIV Antibodies; HIV Infections; Humans; Maraviroc; Molecular Diagnostic Techniques; Triazoles; Viral Tropism; Virology | 2012 |
Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Acquired Immunodeficiency Syndrome; Anti-Retroviral Agents; Chemistry, Pharmaceutical; Drug Design; Drug Industry; HIV; HIV Reverse Transcriptase; Humans; Models, Chemical; Models, Molecular; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Thiazoles; Thymine; Triazoles | 2006 |
Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase.
Topics: Amino Acid Substitution; Drug Design; Drug Resistance, Microbial; HIV; HIV Reverse Transcriptase; Humans; Models, Molecular; Mutation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiazoles; Triazoles | 2000 |
2 trial(s) available for triazoles and HIV
| Article | Year |
|---|---|
Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial.
Topics: Adaptive Immunity; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Dendritic Cells; Female; HIV; HIV Infections; Humans; Immunity, Innate; Lymphocyte Subsets; Male; Maraviroc; Prospective Studies; Triazoles | 2015 |
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
Topics: Adult; Aged; Cyclohexanes; Double-Blind Method; Female; Genotype; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Least-Squares Analysis; Male; Maraviroc; Middle Aged; Patient Selection; Phenotype; Placebos; Triazoles; Viral Load; Young Adult | 2009 |
22 other study(ies) available for triazoles and HIV
| Article | Year |
|---|---|
Administration of Crushed Doravirine via Nasojejunal Feeding Tube in a Patient With Treatment-Experienced Human Immunodeficiency Virus.
Topics: HIV; Humans; Intubation, Gastrointestinal; Pyridones; Triazoles | 2023 |
Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.
Topics: Cyclohexanes; DNA, Viral; Genotype; High-Throughput Nucleotide Sequencing; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Kaplan-Meier Estimate; Leukocytes, Mononuclear; Maraviroc; Treatment Outcome; Triazoles; Viral Tropism | 2013 |
The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
Topics: Adult; Age Factors; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; HIV; HIV Infections; Humans; Maraviroc; Middle Aged; Multivariate Analysis; Retrospective Studies; RNA, Viral; Treatment Outcome; Triazoles; Viral Load | 2015 |
Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Cyclohexanes; Female; Genotype; Genotyping Techniques; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; RNA, Viral; Time Factors; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult | 2015 |
Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
Topics: Acrylates; Active Transport, Cell Nucleus; Animals; Apoptosis; Base Sequence; Cell Cycle Checkpoints; Cell Line; Cell Nucleus; CRISPR-Cas Systems; Exportin 1 Protein; Female; HIV; Humans; Karyopherins; Lymphoma, AIDS-Related; Mice, Nude; Molecular Sequence Data; Molecular Targeted Therapy; NF-kappa B; Protein Binding; Receptors, Cytoplasmic and Nuclear; Reproducibility of Results; rev Gene Products, Human Immunodeficiency Virus; RNA, Messenger; RNA, Viral; Triazoles; Tumor Suppressor Protein p53; Virus Replication; Xenograft Model Antitumor Assays | 2015 |
No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy.
Topics: Anti-HIV Agents; Cyclohexanes; Genotype; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Leukocytes, Mononuclear; Maraviroc; Selection, Genetic; Triazoles; Viral Tropism | 2016 |
Application of the Huisgen cycloaddition and 'click' reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Click Chemistry; Cyclization; Dose-Response Relationship, Drug; HIV; HIV Reverse Transcriptase; Microbial Sensitivity Tests; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles | 2016 |
Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.
Topics: Cyclohexanes; HIV; HIV Fusion Inhibitors; Humans; Inhibitory Concentration 50; Maraviroc; Triazoles; Viral Tropism; Virology | 2016 |
Application of the Triazolization Reaction to Afford Dihydroartemisinin Derivatives with Anti-HIV Activity.
Topics: Amines; Anti-HIV Agents; Artemisinins; Catalysis; Cell Line; HIV; Humans; Inhibitory Concentration 50; Ketones; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Triazoles | 2017 |
Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT).
Topics: Animals; Brain; Cyclohexanes; Drug Evaluation, Preclinical; Feasibility Studies; HIV; HIV Fusion Inhibitors; Intestinal Mucosa; Lymphoid Tissue; Male; Maraviroc; Rats; Tissue Distribution; Triazoles | 2008 |
[Introduction. A brief history of AIDS].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Drug Design; History, 20th Century; History, 21st Century; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Triazoles | 2008 |
An investigation into the anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U) and 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
Topics: Amides; Anti-HIV Agents; Cathepsins; Dideoxynucleosides; HIV; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; Organophosphorus Compounds; Phosphoric Acids; Triazoles | 2009 |
Correlation between the Trofile test and virological response to a short-term maraviroc exposure in HIV-infected patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Cyclohexanes; Female; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, HIV; Triazoles; Viral Load; Young Adult | 2009 |
Tether influence on the binding properties of tRNALys3 ligands designed by a fragment-based approach.
Topics: Binding Sites; HIV; HIV Infections; Ligands; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Reverse Transcription; RNA, Transfer, Amino Acyl; RNA, Viral; Triazoles | 2010 |
Analysis of co-receptor usage of circulating viral and proviral HIV genome quasispecies by ultra-deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment.
Topics: Adult; Antiretroviral Therapy, Highly Active; CCR5 Receptor Antagonists; Cyclohexanes; Female; Genome, Viral; HIV; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Receptors, CCR5; Receptors, HIV; Sequence Analysis, DNA; Sequence Analysis, RNA; Triazoles; Viral Load | 2011 |
TROCAI (tropism coreceptor assay information): a new phenotypic tropism test and its correlation with Trofile enhanced sensitivity and genotypic approaches.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Female; HIV; HIV Infections; Humans; Male; Maraviroc; Microbial Sensitivity Tests; Middle Aged; Triazoles; Viral Tropism; Virus Cultivation | 2010 |
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
Topics: Algorithms; Computer Simulation; Cyclohexanes; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Models, Statistical; Research Design; Software; Triazoles; Viral Load | 2011 |
Penicillium marneffei infection presenting as vulv-ulcer in an HIV-infected woman.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Diagnosis, Differential; Female; HIV; HIV Infections; Humans; Mycoses; Penicillium; Pyrimidines; Triazoles; Ulcer; Voriconazole; Vulvar Diseases; Young Adult | 2011 |
Maraviroc observational study: the impact of expanded resistance testing and clinical considerations for antiretroviral regimen selection in treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Cyclohexanes; Drug Resistance, Viral; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Microbial Sensitivity Tests; Salvage Therapy; Treatment Failure; Triazoles | 2013 |
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.
Topics: Anti-HIV Agents; Azepines; Cell Cycle Proteins; Cyclin-Dependent Kinase 9; HeLa Cells; HIV; Humans; Jurkat Cells; Nuclear Proteins; Phorbol Esters; Phosphorylation; Positive Transcriptional Elongation Factor B; Promoter Regions, Genetic; Ribonucleoproteins, Small Nuclear; RNA Polymerase II; tat Gene Products, Human Immunodeficiency Virus; Transcription Factors; Transcriptional Activation; Transcriptional Elongation Factors; Triazoles; Virus Latency | 2013 |
Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy.
Topics: Antifungal Agents; Carcinoma, Squamous Cell; HIV; HIV Infections; Humans; Male; Middle Aged; Pyrimidines; Skin Neoplasms; Triazoles; Voriconazole | 2008 |
Researchers explore new anti-HIV agents.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclic N-Oxides; Drugs, Investigational; Enfuvirtide; Furans; HIV; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Oximes; Peptide Fragments; Piperazines; Piperidines; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Triazoles | 2002 |